BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in opioid-induced constipation (OIC). Two posters will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in San Diego, California on October 13 and 15, 2013, and the third poster will be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting in Albuquerque, New Mexico on Wednesday, October 16, 2013. AMITIZA is the world's first chloride channel activator that increases intestinal fluid secretion, softens stools, and increases intraluminal fluid volume to initiate colonic transit and improve bowel function independent of motility, thereby facilitating the passage of stool and alleviating symptoms associated with chronic constipation. AMITIZA, via activation of apical ClC-2 channels in the intestinal epithelium, bypasses the antisecretory action of opiates. ACG The first poster listed below will be presented by Dr. Byron Cryer, lead author and Professor of Medicine, University of Texas Southwestern Medical Center, from 3:30 to 7:00 PM PT on Sunday, October 13, 2013. The second poster will be presented by Dr. Shadreck Mareya, Sucampo's Director of Clinical Program Management, on Tuesday, October 15, 2013 from 10:30 AM to 4:00 PM PT:
- Spontaneous Bowel Movement Frequency Is Improved Over 12 Weeks of Lubiprostone Therapy in Opioid-Induced Constipation Patients Regardless of Gender, Age, or Race: Pooled Analysis of Three Well-Controlled Studies (Byron Cryer, MD, FACG, Shadreck Mareya, PhD, Taryn Joswick, BS, PMP, Gayle Dolecek, PD, MPH, Yijun Sun, PhD, Ryuji Ueno, MD, PhD, PhD) Poster 493
- Lubiprostone Effectively Relieves Opioid-Induced Constipation in Patients Using Non-Diphenylheptane Opioids for Non-Cancer Pain: Pooled Analysis of 3 Randomized Controlled Trials (Shadreck Mareya, PhD, Douglas A. Drossman, MD, MACG, Taryn Joswick, BS, PMP, Gayle Dolecek, PD, MPH, Yijun Sun, PhD, Ryuji Ueno, MD, PhD, PhD) Poster 1687
- Lubiprostone for Treatment of Opioid-Induced Constipation Does Not Interfere With Opioid Analgesic Effects in Patients With Non-Cancer Pain (Egilius L. H. Spierings, MD, PhD, Taryn Joswick, BS, PMP, Shadreck Mareya, PhD, Yijun Sun, PhD, Ryuji Ueno, MD, PhD, PhD) Poster 137
Important Safety Information
- AMITIZA (lubiprostone) is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider (HCP) to confirm the absence of such an obstruction prior to initiating AMITIZA treatment.
- Patients taking AMITIZA may experience nausea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their HCP.
- AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. Patients should be instructed to discontinue AMITIZA and inform their HCP if severe diarrhea occurs.
- Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their HCP. Some patients have discontinued therapy because of dyspnea.
- In clinical trials of AMITIZA (24 mcg twice daily vs placebo; N=1113 vs N=316, respectively) in patients with CIC, the most common adverse reactions (incidence > 4%) were nausea (29% vs 3%), diarrhea (12% vs < 1%), headache (11% vs 5%), abdominal pain (8% vs 3%), abdominal distension (6% vs 2%), and flatulence (6% vs 2%).
- In clinical trials of AMITIZA (24 mcg twice daily vs. placebo; N=860 vs. N=632) in patients with OIC, the most common adverse reactions (incidence > 4%) were nausea (11% vs 5%) and diarrhea (8% vs 2%).
- In clinical trials of AMITIZA (8 mcg twice daily vs. placebo; N=1011 vs. N=435, respectively) in patients with IBS-C the most common adverse reactions (incidence > 4%) were nausea (8% vs 4%), diarrhea (7% vs 4%), and abdominal pain (5% vs 5%).
- Concomitant use of diphenylheptane opioids (e.g., methadone) may interfere with the efficacy of AMITIZA.
- The safety of AMITIZA in pregnancy has not been evaluated in humans. Based on animal data, AMITIZA may cause fetal harm. AMITIZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when AMITIZA is administered to a nursing woman. Advise nursing women to monitor infants for diarrhea.
- Reduce the dosage in CIC and OIC patients with moderate and severe hepatic impairment. Reduce the dosage in IBS-C patients with severe hepatic impairment.
Sucampo Forward-Looking StatementThis press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference. Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals). Twitter LinkedIn
CONTACT: Silvia Taylor Senior Vice President, IR, PR, and Corporate Communications 1-240-223-3718 email@example.com